2 21 ABSTRACT 22 Illicit use of psychostimulants, such as cocaine and methamphetamine, constitutes a significant 23 public health problem. Whereas neural mechanisms that mediate the effects of these drugs are 24 well-characterized, genetic factors that account for individual variation in susceptibility to 25 substance abuse and addiction remain largely unknown. Drosophila melanogaster can serve as 26 a translational model for studies on substance abuse, since flies have a dopamine transporter 27 that can bind cocaine and methamphetamine, and exposure to these compounds elicits effects 28 similar to those observed in people, suggesting conserved evolutionary mechanisms underlying 29 drug responses. Here, we used the D. melanogaster Genetic Reference Panel to investigate the 30 genetic basis for variation in psychostimulant drug consumption, to determine whether similar or 31 distinct genetic networks underlie variation in consumption of cocaine and methamphetamine, 32 and to assess the extent of sexual dimorphism and effect of genetic context on variation in 33 voluntary drug consumption. Quantification of natural genetic variation in voluntary 34 consumption, preference, and change in consumption and preference over time for cocaine and 35 methamphetamine uncovered significant genetic variation for all traits, including sex-, exposure-36 and drug-specific genetic variation. Genome wide association analyses identified both shared 37 and drug-specific candidate genes, which could be integrated in genetic interaction networks. 38 We assessed the effects of ubiquitous RNA interference (RNAi) on consumption behaviors for 39 34 candidate genes: all affected at least one behavior. Finally, we utilized RNAi knockdown in 40 the nervous system to implicate dopaminergic neurons and the mushroom bodies as part of the 41 neural circuitry underlying experience-dependent development of drug preference. 42 3 43 AUTHOR SUMMARY 44 Illicit use of cocaine and methamphetamine is a major public health problem. Whereas the 45 neurological effects of these drugs are well characterized, it remains challenging to determine 46 genetic risk factors for substance abuse in human populations. The fruit fly, Drosophila 58 projection plays a role in drug addiction. We asked whether in Drosophila the mushroom bodies 59 could play an analogous role, as they are integrative brain centers associated with experience-60 dependent learning. Indeed, our results suggest that variation in consumption and development 61 of preference for both cocaine and methamphetamine is mediated, at least in part, through a 62 neural network that comprises dopaminergic projections to the mushroom bodies. 63 4 65 130 expression in neurons, glia, the mushroom bodies and dopaminergic neurons in a subset of 131 genes and showed that innate preference and the development of preference for 132 psychostimulant drugs involves dopaminergic neurons and the mushroom bodies, neural 133 elements associated with experience-dependent modulation of behavior. 134 135 RESULTS
melanogaster, presents an excellent model for identifying evolutionarily conserved genes that 48 affect drug consumption, since genetic background and exposure can be controlled precisely. We 49 took advantage of natural variation in a panel of inbred wild derived fly lines with complete genome 50 sequences to assess the extent of genetic variation among these lines for voluntary consumption 51 of cocaine and methamphetamine and to explore whether some genetic backgrounds might show 52 experience-dependent development of drug preference. The drug consumption traits were highly 53 variable among the lines with strong sex-, drug-and exposure time-specific components. We 54 identified candidate genes and gene networks associated with variation in consumption of cocaine 55 and methamphetamine and development of drug preference. Using tissue-specific suppression 56 of gene expression, we were able to functionally implicate candidate genes that affected at least 57 one consumption trait in at least one drug and sex. In humans, the mesolimbic dopaminergic INTRODUCTION 66 Illicit use of cocaine and methamphetamine constitutes a significant public health problem that 67 incurs great socioeconomic costs in the United States and worldwide [1] [2] [3] . Cocaine and the 68 amphetamine class of drugs are potent central nervous system stimulants that act by raising 69 synaptic concentrations of biogenic amines. Cocaine inhibits neurotransmitter reuptake at 70 dopaminergic, serotonergic and noradrenergic synapses [4, 5] . Amphetamine increases 71 neurotransmission by promoting the release of dopamine from presynaptic vesicles through its 72 actions on the vesicular monoamine transporter and subsequent reverse flux of dopamine via 73 the dopamine transporter and through the plasma membrane into the synaptic cleft [6, 7] .
74
Amphetamine, methamphetamine, and methylphenidate are used clinically to treat 75 attention deficit hyperactivity disorder and narcolepsy. Long term use of these compounds, 76 however, can lead to addiction, and ultimately death [8] . The addictive properties of these drugs 77 are mediated through the dopaminergic mesolimbic reward pathway, which projects from the 78 ventral tegmental area via the nucleus accumbens to prefrontal cortex [9] . Although most 79 studies on psychostimulants focus on addiction, addiction represents only one facet of the 80 diverse organismal effects that result from psychostimulant drug abuse. These drugs exert a 81 wide range of physiological and behavioral effects, including suppression of appetite, which can 82 result in malnutrition, and severe cardiovascular, respiratory and renal disorders. Use of cocaine 83 and amphetamine can also cause mental disorders, including paranoia, anxiety, and psychosis 84 [10,11].
85
Susceptibility to the effects of cocaine and methamphetamine is likely to vary among 86 individuals and be determined both by environmental and genetic factors. However, there is 87 limited information regarding the genetic basis of susceptibility to the effects of these drugs in 88 human populations [12] . Twin and adoption studies have focused primarily on alcohol abuse 89 and illicit drugs, such as cannabis, with heritability estimates ranging from ~30-70% [13, 14] .
90
Most studies on psychostimulant addiction to date have centered on candidate genes 5 91 associated with neurotransmission in the mesolimbic projection [12] , and many of these are 92 inconclusive or contradictory. For example, some studies reported that alleles of the dopamine 
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With the exception of L×S, these interaction terms were significant for both the cocaine and 155 methamphetamine analyses (Table 1) .
156
We next performed reduced ANOVA models to quantify broad sense heritabilities (H 2 ) 157 for consumption and change in consumption traits (Table S2 ). We found significant genetic 158 variation in consumption of both drugs and sucrose alone within each sex and exposure, with H 2 159 ranging between 0.20 and 0.38 for cocaine consumption and between 0.22 and 0.30 for 160 methamphetamine consumption ( Fig. 2 , Table S2 ). Further, there was significant genetic 161 variation for the change in consumption of sucrose alone or drug in both sexes between the 162 third and first exposures, with H 2 ranging between 0.14 and 0.18 for cocaine and between 0.17 163 and 0.22 for methamphetamine ( Fig. 2 (Table S2 ). Thus, there is genetic variation for both innate drug 179 preference and experience-dependent drug preference in the DGRP.
180
The heritabilities of consumption traits are low, as is typical for behavioral traits,
181
indicating that environmental factors, including previous experience, predominantly contribute to 182 the observed phenotypic variation. The advantage of performing multiple replicate 183 measurements of each DGRP line is that the broad sense heritabilities of line means (Table S3) 184 used in the GWA analyses (see below) are much greater than heritabilities based on individual 185 vial replicates (Table S2 ).
186
We computed the genetic and phenotypic correlations between males and females for 187 the consumption behaviors, between exposures for consumption and preference, and between 188 solutions ( 
198
In summary, we found that there is extensive genetic variation in consumption and 199 preference as well as change in consumption and preference with repeated exposures for both 200 cocaine and methamphetamine across different genetic backgrounds, and that genetic variation 201 for these traits has significant sex-and drug-specific components.
203
Genome wide association analyses of drug consumption in the DGRP 
213
At a lenient significance threshold of P < 5 x 10 -5 , we identified 1,441 polymorphisms in 214 or near (within 1 kb of the start and end of the gene body) 725 genes for all consumption 215 behaviors related to cocaine, and 1,413 polymorphisms in or near 774 genes for 216 methamphetamine exposure (Table S5 ). The majority of these variants had sex-specific effects.
217
A total of 40 variants and 141 genes overlapped between cocaine and methamphetamine. The (Table S5 ). GO terms involved in nervous system development and function were 235 among the most highly enriched, consistent with the known neurobiological mechanisms of 236 action of these drugs. Finally, we note that ~ 70% of the candidate genes from the GWA 237 analyses have human orthologs, and many of these genes have previously been associated 238 with cocaine or methamphetamine abuse in humans or with behaviors associated with intake 239 and response to various psychoactive substances (alcohol, cannabis, nicotine, opioids) in 240 humans as well as zebrafish, mouse and rat models (Table S6 ). This suggests that cocaine and 241 methamphetamine exert their effects in flies and humans through evolutionarily conserved 242 neural mechanisms.
243
These results suggest a highly polygenic architecture for variation in consumption and 244 drug preference, and that the genetic underpinnings for variation in consumption or preference 245 are both shared and distinct for cocaine and methamphetamine, consistent with the quantitative 246 genetic analyses.
11 247 248
A genetic interaction network for consumption behaviors 249
We next asked whether the genes we identified in the GWA analyses belonged to a known 250 genetic interaction network. Since the consumption behaviors are highly inter-correlated, we 251 queried whether all 1,358 candidate genes from the GWA analyses for both cocaine and 252 methamphetamine combined could be clustered into significant sub-networks based on curated 253 genetic interactions in Drosophila. If we do not allow any missing genes, we find a significant (P 254 = 9.99 × 10 -4 ) network of 81 candidate genes ( Fig. 3 , Table S7 ), most of which (88.9%) are 255 predicted to have human orthologs [55] .
256
We performed enrichment analyses [53,54] to gain insight in the biological context for 257 genes in the network using a false discovery rate < 0.05. Surprisingly, many canonical signaling (Table S8 ) and methamphetamine and sucrose (Table S9) for three consecutive days,
276
separately for males and females, for each of the RNAi and control genotypes, exactly as 277 described for the DGRP lines.
278
We performed three-way fixed effect ANOVAs for each UAS-RNAi and control genotype,
279
separately for males and females (Tables S10, S11 
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To extend and refine our RNAi analysis, we next selected 10 genes (Dop1R1, Ect4, ed, 307 mld, msi, Oct-TyrR, olf413, Snoo, Vha100-1, wmd) from among those that showed phenotypic 318 preference with exposure in males and/or females (Tables S10, S11, Fig.s 4, S4) . With glia-319 specific suppression of gene expression, 4 (7) genes affected consumption of cocaine 320 (methamphetamine), 7 (6) affected a change in consumption with exposure to cocaine 321 (methamphetamine), 3 (0) affected cocaine (methamphetamine) preference, and 2 (3) affected 322 a change in cocaine (methamphetamine) preference with exposure in males and/or females 323 (Tables S10, S11, Fig.s 4, 5, S4) . These effects were largely sex-, drug-and driver-specific. We 14 324
infer from these results that variation in gene expression in both neurons and glia contributes to 325 phenotypic variation in drug intake behaviors.
326
In humans, the mesolimbic dopaminergic projection plays a role in drug addiction. In four traits for Snoo (Tables S10, S11, Fig.s 4, 5, S5 ). These effects are largely sex-, drug-and 345 driver-specific.
346
These results suggest that, despite differences in the genetic underpinnings of 347 susceptibility to cocaine and methamphetamine, phenotypic manifestation of genetic variation in 348 consumption and development of preference for both drugs is channeled through a neural 349 network that comprises dopaminergic projections to the mushroom bodies. can be assembled into a known genetic interaction network (Fig. 3) , which is highly unlikely (P = 389 9.9 x 10 -3 ) to occur by chance. 
Genetic variation in drug consumption behaviors in the DGRP

460
We performed four-way factorial mixed model analyses of variance (ANOVA) to partition 461 variation in consumption in the DGRP: We used the binary GAL4-UAS system for RNAi-targeted knockdown of expression of 511 candidate genes associated with variation in consumption of cocaine or methamphetamine with 512 a weak ubiquitous driver (Ubi156-GAL4) and drivers specific for neurons (elav-GAL4), glia
513
(repo-GAL4), mushroom bodies (201Y-GAL4) and dopaminergic neurons (TH-GAL4). We 514 crossed 3 homozygous GAL4 driver males to 5-7 homozygous females harboring a unique 515 UAS-RNAi transgene or the progenitor control to generate F1 GAL4-UAS-RNAi and GAL4 516 control progeny. We assessed the consumption traits exactly as described above for the DGRP the full ANOVA models. Exact P-values are given in Table S11 . L×S×E terms from the full ANOVA models. Exact P-values are given in Table S12 .
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Exact P-values are given in Table S12 . 
